Cargando…

Role of Temozolomide Regimen on Survival Outcomes in Molecularly Stratified WHO Grade II Gliomas: A Systematic Review

OBJECTIVE/INTRODUCTION: Although a critical chemotherapeutic, temozolomide's optimal regimen for 2016 World Health Organization (WHO) Grade II gliomas remains elusive, hence there is utility in not only cataloging survival outcomes of Grade II glioma subtypes against the background of temozolom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghaffari-Rafi, Arash, Ghaffari-Rafi, Shadeh, Leon-Rojas, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202389/ https://www.ncbi.nlm.nih.gov/pubmed/34211862 http://dx.doi.org/10.4103/ajns.AJNS_186_20

Ejemplares similares

Idiopathic Intracranial Hypertension in the United States: Demographic and Socioeconomic Disparities
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2020)

Application of the sociology theory ethnomethodology to medical education: Utilization of small group learning to combat unconscious bias in patient care
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2020)

Investigatory pathway and principles of patient selection for epilepsy surgery candidates: a systematic review
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2020)

Crossing borders: Fostering early career international networks, critical for medical training and scientific research
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2020)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

Application of an Artificial Intelligence Algorithm to Prognostically Stratify Grade II Gliomas
por: Cesselli, Daniela, et al.
Publicado: (2019)

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
por: Steidl, Eike, et al.
Publicado: (2021)

PROX1 is a predictor of survival for gliomas WHO grade II
por: Elsir, T, et al.
Publicado: (2011)

Protracted hyperthermia and delayed rhabdomyolysis in ecstasy toxicity: A case report
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2020)

Cerebellar Parieto-occipital Posterior Reversible Encephalopathy Syndrome and Cerebral Metamorphopsia Associated with Asymptomatic Atrial Septum Vegetation and Renal Disease: Case Report
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2020)

ACT-18 SHOULD THE DOSE OF TEMOZOLOMIDE BE DECREASED FOR PATIENTS WITH HIGH-GRADE GLIOMAS WHO ARE ON HEMODIALYSIS?
por: Muto, Jun, et al.
Publicado: (2019)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Multivariable analysis of factors associated with USMLE scores across U.S. medical schools
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2019)

T2 mapping of molecular subtypes of WHO grade II/III gliomas
por: Kern, Maike, et al.
Publicado: (2020)

HTLV-1 associated acute adult T-cell lymphoma/leukemia presenting as acute liver failure in Micronesian: A case report
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2021)

Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients
por: Zhang, Baiwei, et al.
Publicado: (2021)

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy
por: Guillevin, R, et al.
Publicado: (2011)

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas
por: Lamb, Lawrence S., et al.
Publicado: (2021)

The Role of Magnetic Resonance Imaging to Inform Clinical Decision-Making in Acute Spinal Cord Injury: A Systematic Review and Meta-Analysis
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2021)

Case Report on Fear of Falling Syndrome: A Debilitating but Curable Gait Disorder
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2019)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Temozolomide in paediatric high-grade glioma: a key for combination therapy?
por: Verschuur, A C, et al.
Publicado: (2004)

High-Grade Glioma: Refined Diagnostics Steering Stratified Therapy
por: Uhl, Martin, et al.
Publicado: (2013)

Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma
por: Wiestler, Benedikt, et al.
Publicado: (2016)

Combination genetic signature stratifies lower-grade gliomas better than histological grade
por: Chan, Aden Ka-Yin, et al.
Publicado: (2015)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
por: Murphy, P S, et al.
Publicado: (2004)

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy
por: Zhou, Xiaofeng, et al.
Publicado: (2016)

Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment
por: Zhi, De-Bao, et al.
Publicado: (2021)

Identification of associations and distinguishing moyamoya disease from ischemic strokes of other etiologies: A retrospective case-control study
por: Sutton, Cori Xiu Yue, et al.
Publicado: (2022)

Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma
por: Choi, Jinhyun, et al.
Publicado: (2020)

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
por: Zhang, Yu-An, et al.
Publicado: (2016)

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide
por: Koekkoek, Johan A. F., et al.
Publicado: (2015)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
por: McDuff, Susan G. R., et al.
Publicado: (2019)

Temozolomide Chronotherapy in Glioma: A Systematic Review
por: Jia, Jason L., et al.
Publicado: (2023)

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
por: Woll, P. J., et al.
Publicado: (1995)

The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas
por: Zhou, Jie, et al.
Publicado: (2022)

Prognosis Individualized: Survival predictions for WHO grade II and III gliomas with a machine learning-based web application
por: Karabacak, Mert, et al.
Publicado: (2023)

The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II
por: Smits, Anja, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gl17nqaom2d3u122i5h3hnd7n8